Nicolaos Christodoulides1, Richard De La Garza2, Glennon W Simmons1, Michael P McRae3, Jorge Wong1, Thomas F Newton4, Regina Smith3, James J Mahoney5, Justin Hohenstein3, Sobeyda Gomez3, Pierre N Floriano1, Humberto Talavera3, Daniel J Sloan3, David E Moody6, David M Andrenyak6, Thomas R Kosten7, Ahmed Haque3, John T McDevitt8. 1. Department of Bioengineering, Rice University, Houston, TX, USA; Department of Chemistry, Rice University, Houston, TX, USA. 2. Menninger Department of Psychiatry & Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA; Department of Pharmacology, Baylor College of Medicine, Houston, TX, USA; Department of Neuroscience, Baylor College of Medicine, Houston, TX, USA. 3. Department of Bioengineering, Rice University, Houston, TX, USA. 4. Menninger Department of Psychiatry & Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA; Department of Pharmacology, Baylor College of Medicine, Houston, TX, USA; Department of Veterans Affairs Medical Center, Houston, TX, USA. 5. Menninger Department of Psychiatry & Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA. 6. Center for Human Toxicology, Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT, USA. 7. Menninger Department of Psychiatry & Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA; Department of Pharmacology, Baylor College of Medicine, Houston, TX, USA; Department of Neuroscience, Baylor College of Medicine, Houston, TX, USA; Department of Veterans Affairs Medical Center, Houston, TX, USA. 8. Department of Bioengineering, Rice University, Houston, TX, USA; Department of Chemistry, Rice University, Houston, TX, USA; Department Biomaterials, Bioengineering Institute, New York University, 433 First Avenue, Room 820, New York, NY 10010-4086, USA. Electronic address: mcdevitt@nyu.edu.
Abstract
OBJECTIVE: There is currently a gap in on-site drug of abuse monitoring. Current detection methods involve invasive sampling of blood and urine specimens, or collection of oral fluid, followed by qualitative screening tests using immunochromatographic cartridges. While remote laboratories then may provide confirmation and quantitative assessment of a presumptive positive, this instrumentation is expensive and decoupled from the initial sampling making the current drug-screening program inefficient and costly. The authors applied a noninvasive oral fluid sampling approach integrated with the in-development chip-based Programmable bio-nano-chip (p-BNC) platform for the detection of drugs of abuse. METHOD: The p-BNC assay methodology was applied for the detection of tetrahydrocannabinol, morphine, amphetamine, methamphetamine, cocaine, methadone and benzodiazepines, initially using spiked buffered samples and, ultimately, using oral fluid specimen collected from consented volunteers. RESULTS: Rapid (∼10min), sensitive detection (∼ng/mL) and quantitation of 12 drugs of abuse was demonstrated on the p-BNC platform. Furthermore, the system provided visibility to time-course of select drug and metabolite profiles in oral fluids; for the drug cocaine, three regions of slope were observed that, when combined with concentration measurements from this and prior impairment studies, information about cocaine-induced impairment may be revealed. CONCLUSIONS: This chip-based p-BNC detection modality has significant potential to be used in the future by law enforcement officers for roadside drug testing and to serve a variety of other settings, including outpatient and inpatient drug rehabilitation centers, emergency rooms, prisons, schools, and in the workplace.
OBJECTIVE: There is currently a gap in on-site drug of abuse monitoring. Current detection methods involve invasive sampling of blood and urine specimens, or collection of oral fluid, followed by qualitative screening tests using immunochromatographic cartridges. While remote laboratories then may provide confirmation and quantitative assessment of a presumptive positive, this instrumentation is expensive and decoupled from the initial sampling making the current drug-screening program inefficient and costly. The authors applied a noninvasive oral fluid sampling approach integrated with the in-development chip-based Programmable bio-nano-chip (p-BNC) platform for the detection of drugs of abuse. METHOD: The p-BNC assay methodology was applied for the detection of tetrahydrocannabinol, morphine, amphetamine, methamphetamine, cocaine, methadone and benzodiazepines, initially using spiked buffered samples and, ultimately, using oral fluid specimen collected from consented volunteers. RESULTS: Rapid (∼10min), sensitive detection (∼ng/mL) and quantitation of 12 drugs of abuse was demonstrated on the p-BNC platform. Furthermore, the system provided visibility to time-course of select drug and metabolite profiles in oral fluids; for the drug cocaine, three regions of slope were observed that, when combined with concentration measurements from this and prior impairment studies, information about cocaine-induced impairment may be revealed. CONCLUSIONS: This chip-based p-BNC detection modality has significant potential to be used in the future by law enforcement officers for roadside drug testing and to serve a variety of other settings, including outpatient and inpatient drug rehabilitation centers, emergency rooms, prisons, schools, and in the workplace.
Authors: A Goodey; J J Lavigne; S M Savoy; M D Rodriguez; T Curey; A Tsao; G Simmons; J Wright; S J Yoo; Y Sohn; E V Anslyn; J B Shear; D P Neikirk; J T McDevitt Journal: J Am Chem Soc Date: 2001-03-21 Impact factor: 15.419
Authors: Maria Rita Parisi; Laura Soldini; Giovanni Di Perri; Simon Tiberi; Adriano Lazzarin; Flavia B Lillo Journal: New Microbiol Date: 2009-10 Impact factor: 2.479
Authors: Karl B Scheidweiler; Erin A Kolbrich Spargo; Tamsin L Kelly; Edward J Cone; Allan J Barnes; Marilyn A Huestis Journal: Ther Drug Monit Date: 2010-10 Impact factor: 3.681
Authors: Archana Raamanathan; Glennon W Simmons; Nicolaos Christodoulides; Pierre N Floriano; Wieslaw B Furmaga; Spencer W Redding; Karen H Lu; Robert C Bast; John T McDevitt Journal: Cancer Prev Res (Phila) Date: 2012-04-09
Authors: Michael P McRae; Glennon W Simmons; Nicolaos J Christodoulides; Zhibing Lu; Stella K Kang; David Fenyo; Timothy Alcorn; Isaac P Dapkins; Iman Sharif; Deniz Vurmaz; Sayli S Modak; Kritika Srinivasan; Shruti Warhadpande; Ravi Shrivastav; John T McDevitt Journal: Lab Chip Date: 2020-06-03 Impact factor: 6.799
Authors: Nicolaos Christodoulides; Richard De La Garza; Glennon W Simmons; Michael P McRae; Jorge Wong; Thomas F Newton; Thomas R Kosten; Ahmed Haque; John T McDevitt Journal: J Drug Abuse Date: 2015-11-23
Authors: Nicolaos J Christodoulides; Michael P McRae; Timothy J Abram; Glennon W Simmons; John T McDevitt Journal: Front Public Health Date: 2017-05-22
Authors: Kritika Srinivasan Rajsri; Michael P McRae; Glennon W Simmons; Nicolaos J Christodoulides; Hanover Matz; Helen Dooley; Akiko Koide; Shohei Koide; John T McDevitt Journal: Biosensors (Basel) Date: 2022-08-10
Authors: Michael P McRae; Glennon W Simmons; Nicolaos J Christodoulides; Zhibing Lu; Stella K Kang; David Fenyo; Timothy Alcorn; Isaac P Dapkins; Iman Sharif; Deniz Vurmaz; Sayli S Modak; Kritika Srinivasan; Shruti Warhadpande; Ravi Shrivastav; John T McDevitt Journal: medRxiv Date: 2020-04-22